- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05422391
The Acute Effects of Caloric Restriction on Anthropometrics, Metabolism, and Cardiovascular Health in Overweight Adults
Evaluating the Short-Term Effects of 3 Days of Caloric Restriction/Intermittent Fasting Using the Plexus(R) Program on Anthropometrics, Metabolism, Markers of Cardiovascular Health in Overweight/Obese Men and Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
According to the US Centers for Disease Control, more than 42% of adults are classified as obese, and approximately 74% of US adults are classified as overweight (body mass index of 25.0 to < 30 kg/m2) or obese (>30 kg/m2) (Ow/Ob). The costs on human health are profound, increasing the risk of heart disease, stroke, type 2 diabetes, and certain cancers, and ultimately increasing morbidity associated with these chronic diseases. Obesity and the negative sequelae inflict staggering economic costs, estimated at $147 billion, and that was in 2008. Therefore, understanding and developing interventions that can help address Ow/Ob can reduce the risk of chronic disease, reduce healthcare costs, and likely improve quality of life.
One such intervention has been through altering diet and/or physical activity. However, prior systematic review and meta-analysis suggests that when comparing diet alone vs. exercise alone, dietary interventions result in ~3-fold greater weight loss (11 vs 3 Δkg). While the additional benefits of exercise are not be discounted, engaging dietary approaches can be a highly effective way to promote weight loss. Caloric restriction (CR) has long been touted as an effective method of inducing weight loss, although there are also issues with adherence and maintenance with such an approach. This study is seeking to understand the acute metabolic changes with engaging in a 3-day caloric restriction, which would typically be part of an intermittent fasting dietary regimen.
Specific Aim 1. Document the efficacy of the 3 day IF/CR on inducing short term weight loss, the nature of the weight loss changes (body composition), changes in anthropometrics (waist and hip circumference), changes in resting metabolic rate and changes in metabolic flexibility (relative utilization of fats versus carbohydrates).
Specific Aim 2. Explore the physiological responses to the 3 day IF/CR with the Plexus 3 day reset program through analysis of blood plasma for levels of insulin, glucose, lipid profile (total cholesterol, high- and low-density cholesterol (HDL/LDL)), pro- and anti-inflammatory mediators (Tumor Necrosis Factor-alpha, TNFa and Cortisol, respectively), ketones, thyroid stimulating hormone (TSH), and hormones related to hunger and satiety and thus energy intake (protein YY (PYY), neuropeptide Y (NPY), Ghrelin, and Leptin).
Specific Aim 3. Ascertain any possible changes in clinically relevant parameters such as heart rate, heart rate variability (HRV), blood pressure (central and peripheral), and vascular stiffness (augmentation index, AIx).
Hypothesis: The investigators hypothesize that the nutritional intervention will induce weight loss, changes in anthropometrics/body composition (i.e. decreased body water), resting metabolic rate, and alterations in metabolic flexibility. These measures will be explained, at least, in part, by alterations in specific blood biomarkers. The investigators also hypothesize that the 3 day IF/CR will result in improved indicators of cardiovascular health.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Saratoga Springs, New York, United States, 12866
- Skidmore College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Overweight or obese (body mass index, BMI > 27.5 kg/m2)
- Weight stable (± 4.4 lb) for > 6 months prior
- 25 to 65 years of age
- Participants will be expected to be otherwise relatively healthy without uncontrolled chronic disease (e.g. cardiovascular, metabolic, or pulmonary) and 2 or fewer positive risk factors for cardiovascular disease (CVD) (e.g. high blood pressure, high cholesterol, etc) as described by the American College of Sports Medicine (ACSM)/American Heart Association (AHA) Criteria.
- Cleared by Physician
Exclusion Criteria:
- Subjects who present with more than 2 CVD risk factors (AHA/ACSM criteria) or have uncontrolled/overt cardiovascular, pulmonary, or metabolic disease (Diabetes Mellitus)
- Not cleared by their physician.
- Recent blood donation (<8 weeks)
- Those who have cancer or are being treated for cancer.
- Women who are currently pregnant, breastfeeding, attempting to conceive, or amenorrheic (not associated with menopause).
- Anyone who presents with food allergies to coconuts, dairy, soy, stevia, or nuts will also be excluded.
- Those with eating disorders should not partake in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Pre- post-dietary intervention
Single arm pre-post dietary intervention (caloric restriction)
|
Participants will consume ~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight
Time Frame: (days 0 and 4)
|
Change in total body weight
|
(days 0 and 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in total body water
Time Frame: (days 0 and 4)
|
Assessed via bioelectric impedance analysis (BIA)
|
(days 0 and 4)
|
|
Change in body fat (%)
Time Frame: (days 0 and 4)
|
Assessed via bioelectric impedance analysis (BIA)
|
(days 0 and 4)
|
|
Change in lean mass (kg)
Time Frame: (days 0 and 4)
|
Assessed via bioelectric impedance analysis (BIA)
|
(days 0 and 4)
|
|
Change in waist circumference
Time Frame: (days 0 and 4)
|
Changes in waist circumference (cm) using Gulick tape measure
|
(days 0 and 4)
|
|
Change in hip circumference
Time Frame: (days 0 and 4)
|
Changes in hip circumference (cm) using Gulick tape measure
|
(days 0 and 4)
|
|
Changes in waist to hip ratio
Time Frame: (days 0 and 4)
|
Changes in waist:hip ratio derived from waist and hip circumferences
|
(days 0 and 4)
|
|
Change in resting metabolic rate
Time Frame: (days 0 and 4)
|
Change in resting metabolic rate assessed using the ventilated hood technique and indirect calorimetry (TrueOne2400, Parvomedics).
|
(days 0 and 4)
|
|
Change in substrate utilization
Time Frame: (days 0 and 4)
|
Change in resting-fasted substrate utilization (Fat vs. Carbohydrate) using the ventilated hood technique and indirect calorimetry (TrueOne2400, Parvomedics).
|
(days 0 and 4)
|
|
Change peripheral blood pressure
Time Frame: (days 0 and 4)
|
Changes in peripheral blood pressure assessed using oscillometric cuff technique on the brachial artery (Sphygmocor Xcel).
|
(days 0 and 4)
|
|
Change in central blood pressure
Time Frame: (days 0 and 4)
|
Change in estimated central blood pressure, assessed using oscillometric cuff technique and generalized transfer function (Sphygmocor Xcel).
|
(days 0 and 4)
|
|
Change in augmentation index
Time Frame: (days 0 and 4)
|
Changes in augmentation index (a marker of vascular stiffness) will be assessed using oscillometric cuff technique and generalized transfer function (Sphygmocor Xcel).
|
(days 0 and 4)
|
|
Change in heart rate variability
Time Frame: (days 0 and 4)
|
Changes in time-domain based heart rate variability will be assessed using standard ECG with subsequent automated analysis with artifact correction (H7 PolarUSA and Elite HRV).
|
(days 0 and 4)
|
|
Changes in blood lipid profile
Time Frame: (days 0 and 4)
|
Changes in blood lipids (total Cholesterol, TC; low density lipoprotein LDL Cholesterol; high density lipoprotein, HDL Cholesterol; and TC:HDL ratio) will be assessed using standard techniques (Cholestech System)
|
(days 0 and 4)
|
|
Changes in blood glucose regulation
Time Frame: (days 0 and 4)
|
Changes in fasting blood glucose and insulin using standard techniques.
|
(days 0 and 4)
|
|
Changes in blood markers of inflammation
Time Frame: (days 0 and 4)
|
Changes in blood inflammatory markers (Tumor Necrosis Factor alpha (TNFa) and Cortisol) using standard techniques.
|
(days 0 and 4)
|
|
Changes in circulating regulators of metabolism
Time Frame: (days 0 and 4)
|
Changes in blood levels of the metabolically active hormones (thyroid stimulating hormone (TSH), protein yy (PYY), neuropeptide y (NPY), Ghrelin, and Leptin) using standard biochemical techniques.
|
(days 0 and 4)
|
|
Changes in perceptual indicators
Time Frame: Days 0 through 4
|
Changes in self-reported sensations of hunger, fullness, satiety, and gastrointestinal discomfort will be assessed using visual analog scales (VAS).
The VAS is 100 mm line ranging from 0 to 100, where a participant who marks 0 indicates "none" (not hungry at all or no gastrointestinal distress) vs. marking at 100 would indicate the maximal response ("severely hungry" or "severe gastrointestinal distress").
The hunger, fullness, and satiety ratings are not necessarily worse or better type outcomes, but simply descriptive.
The magnitude is quantified by measuring the distance the participant marks on the 100mm line.
In the case of gastrointestinal distress, scores over 51, or large increases in GID would be considered a less favorable outcome and the higher the score the worse the outcome on this specific item.
|
Days 0 through 4
|
|
Changes in sleep health
Time Frame: Days 0 through 4
|
Changes in sleep quantity and quality will be assessed using the consensus sleep diary, core form.
This form records times for going to sleep, falling asleep, waking during the night, waking in the morning.
There is only one likert type item which ask participants to subjectively rate the quality of sleep from very poor to very good, and reports of poor or very poor sleep would be considered worse outcomes, particularly those with changes in response to the dietary outcome.
|
Days 0 through 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen Ives, Ph.D., Skidmore College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2204-1028
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
Clinical Trials on 3 day caloric restriction/metabolic reset
-
University of OttawaConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedObesity | Weight Loss | Appetitive Behavior
-
University of LuxembourgRecruitingChronic Inflammation | Long CovidLuxembourg
-
University Hospital MuensterCharite University, Berlin, GermanyUnknown
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline; University of WashingtonCompletedProstate Cancer | Castration-resistant, MetastaticUnited States
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchCompletedMild Cognitive ImpairmentGermany